Traduction de «change in marketable » (Néerlandais → Français) :

TERMINOLOGIE

Chang-Davidson-Carlson-syndroom
syndrome d'hypogonadisme hypogonadotrope-rétinite pigmentaire

TRADUCTIONS EN CONTEXTE

First quarter Q1 2010 Q1 2009 Change USD m USD m USD m Change in cash and cash equivalents 2 172 –463 2 635 Change in marketable securities, financial debt and financial derivatives –3 664 –1 903 –1 761
Variation des titres de placement négociables, de la dette financière et des instruments financiers dérivés –3 664 –1 903 –1 761

Acquisitions of subsidiaries -26 666 -890 -25 776 Change in marketable securities 12 821 -7 508 20 329 Cash flow used for investing activities -15 169 -10 026 -5 143 Change in current and non-current financial debts 12 258 6 810 5 448 Dividends paid to shareholders of Novartis AG -4 486 -3 941 -545 Treasury share transactions 438 80 358 Other financing cash flows -34 1 -35 Cash flow from financing activities 8 176 2 950 5 226 Translation effect on cash and cash equivalents -5 86 -91 Change in cash and cash equivalents 2 492 735 1 757 Cash and cash equivalents at January 1 2 894 2 038 856 Cash and cash equivalents at September 30 5 386 2 773 2 613
Acquisitions de filiales -26 666 -890 -25 776 Variation des titres de placement 12 821 -7 508 20 329 Flux de trésorerie des activités d’investissement -15 169 -10 026 -5 143 Variation des dettes financières à court et long terme 12 258 6 810 5 448 Dividendes versés aux actionnaires de Novartis AG -4 486 -3 941 -545 Transactions sur actions propres 438 80 358 Autres flux de financement -34 1 -35 Flux de trésorerie des activités de financement 8 176 2 950 5 226 Effet nets des écarts de conversion sur la trésorerie et les équivalents de trésorerie -5 86 -91

Acquisitions of subsidiaries -26 167 -859 -25 308 Change in marketable securities 15 837 -3 114 18 951 Cash flow used for investing activities -10 662 -4 452 -6 210 Change in current and non-current financial debts 7 077 162 6 915 Treasury share transactions 131 276 -145 Other financing cash flows -4 5 -9 Cash flow from financing activities 7 204 443 6 761 Translation effect on cash and cash equivalents 59 38 21 Change in cash and cash equivalents -172 -817 645 Cash and cash equivalents at July 1 5 558 3 590 1 968 Cash and cash equivalents at September 30 5 386 2 773 2 613
Acquisitions de filiales -26 167 -859 -25 308 Variation des titres de placement 15 837 -3 114 18 951 Flux de trésorerie des activités d’investissement -10 662 -4 452 -6 210 Variation des dettes financières à court et long terme 7 077 162 6 915 Transactions sur actions propres 131 276 -145 Autres flux de financement -4 5 -9 Flux de trésorerie des activités de financement 7 204 443 6 761 Effet nets des écarts de conversion sur la trésorerie et les équivalents de trésorerie 59 38 21

2009 2008 Change USD m USD m USD m Change in cash and cash equivalents 856 –3 322 4 178 Change in marketable securities, financial debt and financial derivatives 3 852 –5 332 9 184
2009 2008 Variation M USD M USD M USD Variation de la trésorerie et des équivalents de trésorerie 856 –3 322 4 178

Second quarter Q2 2009 Q2 2008 Change USD m USD m USD m Change in cash and cash equivalents 2 015 7 138 –5 123 Change in marketable securities, financial debt and financial derivatives –456 –6 042 5 586
Premier semestre S1 2009 S1 2008 Variation M USD M USD M USD Variation de la trésorerie et des équivalents de trésorerie 1 552 8 709 –7 157

2008 2007 Change USD m USD m USD m Change in cash and cash equivalents –3 322 1 545 –4 867 Change in marketable securities, financial debt and financial derivatives –5 332 5 206 –10 538
2008 2007 Variation M USD M USD M USD Variation de la trésorerie et des équivalents de trésorerie –3 322 1 545 –4 867

USD m USD m USD m Change in cash and cash equivalents 735 –911 1 646 Change in marketable securities, financial debt and financial derivatives 312 –9 163 9 475
M USD M USD M USD Variation de la trésorerie et des équivalents de trésorerie 735 –911 1 646

The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.
The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.